Jailed drug-company founder Martin Shkreli and an associate violated competition laws by working to block rivals from introducing generic forms of an antiparasite drug, the Federal Trade Commission and the New York attorney general allege in a new lawsuit. The efforts by Mr. Shkreli to prevent competitors from producing generic versions of the drug, called Daraprim, continue to this day, the complaint filed Monday in federal court in New York says. Daraprim treats toxoplasmosis, a parasitic infection.

Source: Wall Street Journal January 27, 2020 23:26 UTC